




- Megan Fonteno is currently a PGY-2 Oncology Pharmacy Resident at the University of Utah Huntsman Cancer Institute.
- She earned her PharmD from Auburn University's Harrison School of Pharmacy in Auburn, AL.
- She completed her PGY-1 Pharmacy Practice Residency at Piedmont Columbus Regional Midtown Hospital in Columbus, GA.
- Megan would love to pursue a career as a clinical oncology pharmacist after graduating from her PGY-2 program. Additionally, she would love to teach an oncology elective in the future as well.



USHP



Deprived and Staying Alive! – with novel therapies in advanced prostate cancer

Megan Fonteno, PharmD

PGY2 Pharmacy Oncology Resident Huntsman Cancer Institute | University of Utah <u>Megan.Fonteno@hsc.utah.edu</u> | 904.708.6912

Disclosure

- Relevant Financial Conflicts of Interest
- CE Presenter, Megan Fonteno, PharmD:
 None
- CE mentor, Emma Jones, PharmD, BCOP:
 None
- Off-Label Uses of Medications
- None

USHP

USHP

Pharmacist Learning Objectives

Describe the overall impact of prostate cancer therapies on patient outcomes

Develop and/or assess an individualized treatment plan for a patient with advanced prostate cancer

Compare and contrast different prostate cancer therapies based on mechanisms of action, indicated use and side effect profile


USHP


Technician Learning Objectives


Discuss barriers to access of medications used in advanced prostate cancer


Select the appropriate trade name for advanced prostate cancer therapy


Explain the reasoning behind the use of androgen deprivation therapies for advanced prostate cancer











































Study Information	Relugolix*	Leuprolide	p-value	
Patient Population	Relugolix 360	atients with metastatio mg load day 1 + 120r setate 22.5mg SQ inje	ng daily OR	
Achieve & maintain testosterone <50ng/dL	96.7%	88.8%	p<0.0001	
MACE** Risk w/o history	2.9%	6.2%	p<0.001	
MACE** Risk w/ history	3.6%	17.8%	p<0.001	
**MACE = major adverse cardio		ly op day 4 of th		US











Relugolix	
Preparation \rightarrow specialty pharmacy	
120mg tablet	
Cost	
 120mg = \$92.52 \$2775.60/month 	
Storage	
Room temperatureDispense in original container	USHI
relugalix) (prescribing information).	
















	The Latitude	Trial		
	Study Information	Abiraterone + Prednisone	Placebo	p-value
	Patient Population	 1199 patients w/ newly diagnost sensitive ADT + abiraterone acetate 1 ADT + placebos Median follow-up: 30.4mo 	-	
	Overall Survival [OS] at 3 yrs	66%	49%	p<0.001
	Progression-free survival	33.0mo	14.8mo	p<0.001
				USH
N Engi J	Ned 2017; 377:352-360			


















The Titan Tria	I		
Study Information	Apalutamide	Placebo	p-value
Patient Population	 525 pts with metastatic, castration-sensitive PC received: Apalutamide 240mg daily + ADT Placebo + ADT 		
OS at 48mo	65%	52%	P<0.001
Radiographic PFS	68.2%	47.5%	p<0.001
Time to PSA progression	NE	12.9%	
*NE: not estimated			(USH
id 2019; 381:13-24 1021; 11-12			


















Study Information	Olaparib	Enzalutamide/Abiraterone	p-value
Patient Population	who had dx progree • Cohort A: 245pt	static castration-resistant prosta resion on new hormonal agents with \geq 1 alteration in BRCA1/2, with alteration in any 12 other c	or ATM
PFS	7.4mo	3.6mo	p<0.001
os	18.5mo	15.1mo (81% crossed over)	
			USF


Study Information	Rucaparib 600mg BID
Patient Population	 277 pts with metastatic castration-resistant prostate cancer with homologous recombination deficiency Pt currently on 2nd or 3rd line therapy
Objective Response Rate [ORR]	43.9% at 13.1mo
PSA Response	52.0%
Conclusions so far	 Demonstrates promising efficacy in mCRPC and BRCA No objective responses observed in ATM/CDK12 alterations
	USH

















Deprived and Staying Alive! – with novel therapies in advanced prostate cancer

CE Code: (USHP will fill in)

Megan Fonteno, PharmD PGY2 Pharmacy Oncology Resident

Huntsman Cancer Center | University of Utah Megan.Fonteno@hsc.utah.edu | 904.708.6912